

Disclaimer: The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

More Details on: www.microport.com.cn

Email: ir@microport.com
Tel (021) 38954600
Fax (021) 50801305

Patient Enrollment for TARGET II achieves completion

TARGET II, a prospective, multicenter, single-arm, observed registered clinical trial of Firehawk Raparmacyin Target Eluting Coronary Stent System sponsored by MicroPort Medical (Shanghai) Co., Ltd, completed the patient enrollment process on Feb 13th, 2012. To date, all patient enrollments for the pre-marketing clinical study of Firehawk have been achieved. The clinical study has now entered the clinical follow-up and data-processing stage.

There are three phases in Firehawk pre-marketing clinical investigation study: FIM (First-In-Man), TARGET I and TARGET II. The patient recruitment of FIM was completed in January 2010. 4-month OCT follow-up, 4- and 13-month angiographic follow-ups and 12-month clinical follow-up were then sequentially completed. TARGET I was a prospective, multicenter, randomized controlled clinical trial of Firehawk. The patient enrollment of Target I was completed in May, 2011 and the result of a 9-month angiographic follow-up and 12-month clinical follow-up will be published at TCT 2012.

There were a total of 1, 261 patents been enrolled in the pre-marketing clinical investigation of Firehawk in China. The clinical trial is a milestone, as it is the first-ever trail in compliance with the SFDA's guidance on Drug-Eluting Coronary Stents

Systems:-Clinical Studies (Draft). It is also the largest clinical study on drug eluting coronary stent systems that ever been conducted in China.

MicroPort Orthopedics Product got CE certificate once again

Locking Compression Plate System (including metallic medical bone screws) and Posterior Cervical Fixation System from MicroPort Orthopedics Co., Ltd. were CE marked by TUV SUD recently, and the whole QMS successfully passed the annual surveillance audit, which enriched our product line up for the international market.

MicroPort Lifesciences' Re-Registration for La Fenice[®] Approved

The re-registration for La Fenice[®] from MicroPort Lifesciences (Shanghai) Co., Ltd. was approved on the date of 6th of February.



Dr. Zhaohua Chang was elected as Vice Chairman of the CPPCC of Pudong New Area

The first meeting of the 5th Committee of the Chinese People's Political Consultative Conference of Pudong New Area was concluded successfully on January 7th at the China Executive Leadership Academy, Pudong, Shanghai. Wu Quanguo, the newly elected Vice Chairman of CPPCC of Pudong New Area chaired the conference, at which the list of the newly elected members was published. Dr. Zhaohua Chang, Executive Director and Chairman of MicroPort Medical (Shanghai) Co., Ltd. was elected as Vice Chairman of the CPPCC of Pudong New Area.

A Fund-Raising Campaign for Zun Yi Hope Primary School

MicroPort has launched a company-wide fund-raising campaign for Zun Yi Hope Primary School (Guizhou Province) recently. Up to the 27th of February, it had received a total of 1,028,399.81 RMB in donation, among which 750,000 RMB was donated by the company. 801 staff members participated in the fund-raising event and the total donation amounted to 278,399.81 RMB.



MicroPort Ranked in Forbes' "China's Most Promising Listed Companies" List

Forbes China released its annual list of "China's Most Promising Companies" on 4th of January, 2012. It is the 8th time that Forbes conducted independent and comprehensive analysis in regard of Chinese small and median size corporations. It is the first time that the research results are categorized into listed and non-listed companies. MicroPort ranks 66 of the "China's Most Promising Listed Companies".

